Journal Article (Review Article)

DKFZ-2025-01847

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Chimeric antigen receptor T-cells for patients with hematologic malignancies. [Chimäre Antigen-Rezeptor-T-Zellen für Patientinnen und Patienten mit hämatologischen Neoplasien].

Schubert, M.-L. ; Dreger, P. ; Schmitt, M. (Last author)DKFZ*

2025
Steinkopff Darmstadt

This record in other databases:

Please use a persistent id in citations: doi:10.1007/s00393-025-01703-2

Abstract: The targeted and personalized cell and gene therapy with autologous chimeric antigen receptor (CAR) transduced T‑cells (CAR T‑cells) has become established as the standard therapy for patients with B‑cell diseases, such as CD-19 positive leukemia and lymphomas and B‑cell maturation antigen (BCMA) positive multiple myeloma (MM). This therapy has been approved in Europe since 2018 and is administered in more than 50 clinics in Germany. With increasing experience and expertise in understanding of the principles of action and underlying mechanisms as well as mitigation of side effects have significantly improved. In the near future expansion of CAR T‑cell applications are to be expected, aimed at addressing further targets and therefore other disease entities. Currently, the indications have already expanded beyond hematology and oncology to rheumatology, neurology and other fields.

Keyword(s): B‑cell diseases ; CAR T‑cells ; Cell and gene therapy ; Indications ; Principle of action

Note: 2025 Oct;84(8):601-611

---

Contributing Institute(s):

1. DKTK HD zentral (HD01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Springer ; DEAL Springer ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---